Page 26 - Systemic Sclerosis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cumberland Pharmaceuticals Reports 9% Revenue Growth In 2020 News provided by Share this article NASHVILLE, Tenn., March 9, 2021 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology and rheumatology, today announced fourth quarter and full year 2020 financial results. Net Revenues for the fourth quarter were $10.3 million, up 10% over the prior year period. For the full year 2020, Net Revenues totaled $37.4 million, a 9% increase over 2019. The company also recorded an additional $3.2 million in r...

Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2020 Financial Results News provided by Share this article NASHVILLE, Tenn., March 2, 2021 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release fourth quarter and annual 2020 financial results and Company update after the market closes on Tuesday, Mar. 9, 2021. A conference call and live internet webcast will be held on Tuesday, March 9, 2021, at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (...

CiVi Biopharma to Participate in HC Wainwright BioConnect 2021 Conference News provided by Share this article CHEVY CHASE, Md., Jan. 8, 2021 /PRNewswire/ --  CiVi Biopharma, Inc. ("CiVi" or "the Company"), a privately held company focused on creating novel therapies against diseases where the unmet medical need exists, today announces that Company management will participate in the upcoming HC Wainwright BioConnect 2021 Conference taking place virtually from January 11-14, 2021.  Shalom Jacobovitz, Chief Executive Officer of CiVi Biopharma, will deliver a corporate overview in a webcast pr...

Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement Merger brings lead compound CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need Concurrent PIPE financing to be used to fund clinical trials for CM-101 in fibrotic indications, focusing on two rare diseases and backed by leading healthcare-focused investors OrbiMed and Peter Thiel CAMBRIDGE, Mass. and TEL-AVIV, Israel, Dec. 15, 2020 — ...

Published: Dec 16, 2020 By Joseph Constance A healthy immune system defends the body against disease and other conditions. However, if the immune system malfunctions, it can attack healthy cells, tissues and organs. Autoimmune disease impacts different parts of the body, weakening functionality. It may be life-threatening. Researchers are aware of more than 80 diseases that occur when the immune system attacks the body’s own organs, tissues and cells. The more common autoimmune diseases include type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus and inflammatory bowe...